Monaco Asset Management SAM Cuts Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Monaco Asset Management SAM lessened its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 53.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 177,500 shares of the company's stock after selling 207,164 shares during the period. Monaco Asset Management SAM owned 0.31% of Ginkgo Bioworks worth $1,012,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Barclays PLC lifted its holdings in Ginkgo Bioworks by 353.6% in the fourth quarter. Barclays PLC now owns 54,166 shares of the company's stock valued at $531,000 after buying an additional 42,224 shares during the period. Forbes J M & Co. LLP boosted its position in shares of Ginkgo Bioworks by 56.0% during the 1st quarter. Forbes J M & Co. LLP now owns 1,094,564 shares of the company's stock valued at $6,239,000 after purchasing an additional 392,832 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Ginkgo Bioworks by 15.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,995 shares of the company's stock worth $412,000 after purchasing an additional 5,746 shares during the period. Renaissance Technologies LLC increased its holdings in Ginkgo Bioworks by 65.1% in the fourth quarter. Renaissance Technologies LLC now owns 114,654 shares of the company's stock worth $1,126,000 after purchasing an additional 45,200 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Ginkgo Bioworks in the 4th quarter valued at $665,000. 78.63% of the stock is currently owned by institutional investors.

Ginkgo Bioworks Price Performance

Shares of DNA stock traded up $0.22 on Thursday, reaching $13.10. 1,210,157 shares of the company were exchanged, compared to its average volume of 1,603,418. The company has a 50-day moving average of $9.82 and a 200-day moving average of $9.29. Ginkgo Bioworks Holdings, Inc. has a one year low of $5.00 and a one year high of $16.85.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 198.84% and a negative return on equity of 52.35%. The firm had revenue of $48.32 million for the quarter, compared to the consensus estimate of $38.70 million. Equities research analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.